What Is the Role of Injectables in the Modern Era of MS Treatment?

The "Platform Injectables"

IFNβ-1b: 11-Year Follow-Up of BENEFIT Trial in CIS

IM IFNβ-1a 15-Year Follow-Up: Mean EDSS

Long-Term Results With GA: 15-Year Open-Label Study

UK Multiple Sclerosis Risk-Sharing Scheme: 6 Years of Injectables

Injectables: Long-Term Safety

Strategies for Minimizing Injection-Site Reactions

ADVANCE: SC PegIFNβ-1a

GALA 3-Year Results: Efficacy of GA 40 mg/mL 3X Weekly

SC PegIFNβ-1a and GA 40 mg/mL 3X Weekly: Safety

Adherence With New Formulations of SC IFNβ-1a and GA

Using Injectables in Clinical Practice: Considerations

Importance of Injectables in the Treatment Armamentarium

Role of Platform Injectables: Lessons From Hypertension Management

Clinical Trials With Injectables: Applying Data to Today's MS Patients

Sequencing With Platform Injectables

CombiRx: IM IFNβ-1a Plus GA

SENTINEL: IM IFNβ-1a Plus Natalizumab

Combining Immunomodulators: Lessons From Rheumatoid Arthritis Management

Challenges in Developing Follow-On Products

IFNβ Plus Teriflunomide

TV-5010 Development: Short-Term Preclinical and Clinical Studies Did Not Raise Concerns

TV-5010 Development: Long-term Toxicology Studies Raised Concerns

Meeting the Challenges in Developing Follow-On Products: Regulatory Guidance

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)